MigraineMigraine With AuraMigraine Without AuraChronic Migraine
Investigational drug(s) / intervention(s)
Rimegepant 75 MG Disintegrating Oral Tablet
Rimegepant 75 MG Disintegrating Oral Tablet: Patients using Rimegepant 75 mg orally disintegrating tablet to treat acute migraine attacks
Study summary
The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as acute migraine treatment in a cohort of episodic or chronic migraine patients.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III).
* At least 3 MMDs
* Good compliance to study procedures
* Availability of headache diary at least of the preceding months before enrollment
Exclusion Criteria:
* Subjects with contraindications for use of gepants;
* Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments;
* medical comorbidities that could interfere with study results;
* Pregnancy and breastfeeding.
Primary outcome measure(s)
Headache pain freedom at 2 hours post-dose during the first attack — 2 hours post-dose The percentage of subjects that report no headache pain at 2 hours after drug intake. Pain will be measured on a 4 point Likert scale (0=none, 1=mild, 2=moderate, 3=severe).
Occurrence of treatment-emergent adverse events — 12 weeks To evaluate the safety and tolerability of Rimegepant in migraine subjects.
Trial sites (2)
Facility
City
Region
Status
SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi
Florence
Italy
Recruiting
IRCCS National Neurological Institute "C. Mondino" Foundation
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
